Leriglitazone

Leriglitazone is a PPAR-gamma agonist and metabolite of the glitazone pioglitazone. It is developed for adrenomyeloneuropathy, and other neurodegenerative diseases.^[1][2][3][4]

Leriglitazone

Clinical data
Other names	Hydroxypioglitazone
ATC code	A16AX23 (WHO)
Identifiers
IUPAC name 5-[[4-[2-[5-(1-Hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione
CAS Number	146062-44-4
PubChem CID	4147757
DrugBank	DB15021
ChemSpider	3360070
UNII	K824X25AYA
KEGG	D11603
ChEMBL	ChEMBL1267
CompTox Dashboard (EPA)	DTXSID30399914
Chemical and physical data
Formula	C19H20N2O4S
Molar mass	372.44 g·mol−1
3D model (JSmol)	Interactive image
SMILES CC(C1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3)O
InChI InChI=1S/C19H20N2O4S/c1-12(22)14-4-5-15(20-11-14)8-9-25-16-6-2-13(3-7-16)10-17-18(23)21-19(24)26-17/h2-7,11-12,17,22H,8-10H2,1H3,(H,21,23,24) Key:OXVFDZYQLGRLCD-UHFFFAOYSA-N

Society and culture

Legal status

In January 2024, the European Medicines Agency (EMA) recommended the refusal of the marketing authorization for leriglitazone (Nezglyal) requested by Minoryx Therapeutics S.L.^[5] In May 2024, the EMA confirmed its recommendation to refuse marketing authorization for leriglitazone.^[5] Leriglitazone was intended for the treatment of cerebral adrenoleukodystrophy.^[5]